Topics

STAT Plus: Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins

15:49 EST 12 Feb 2020 | STAT

Two large insulin manufacturers are objecting to an FDA proposal designed to make it easier for other companies to develop lower-cost alternatives.

Original Article: STAT Plus: Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins"

Quick Search

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...